Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NeuroRx Says COVID-19 Drug Improves Survival If Overstretched ICUs Excluded

Will Seek EUA Shortly

Executive Summary

Therapy shows some promise in helping COVID-19 respiratory failure patients but the US FDA may question company’s data cut. 

You may also be interested in...



Finance Watch: Janux Offering Makes 47 Biopharma IPOs In 2021, So Far

Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.

Positive Signs For Valneva’s COVID-19 Vaccine, But Efficacy Data And Orders Still Lacking

Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.

Can Sarepta Beat Pfizer To A Duchenne Gene Therapy Breakthrough?

As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel